[{"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-001", "question": "A 45-year-old man with a history of relapsing-remitting multiple sclerosis presents with acute onset of bilateral leg weakness and urinary retention. MRI shows a new T2-hyperintense lesion at T10 with gadolinium enhancement. Despite high-dose intravenous methylprednisolone, symptoms worsen over 48 hours. CSF analysis reveals elevated IgG index and oligoclonal bands. What is the most appropriate next step in management?", "options": ["Initiate plasma exchange", "Administer rituximab", "Start fingolimod", "Perform lumbar puncture for repeat CSF analysis", "Switch to natalizumab"], "answer": "A", "answer_index": 0, "explanation": "Plasma exchange is the most appropriate next step for severe acute demyelinating attacks unresponsive to corticosteroids in multiple sclerosis, as it rapidly removes circulating autoantibodies and inflammatory mediators. Rituximab and natalizumab are disease-modifying therapies not indicated for acute management, while fingolimod is contraindicated in active inflammation; repeat CSF analysis is unnecessary with established diagnosis.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a severe acute MS relapse (transverse myelitis pattern with bilateral leg weakness, urinary retention, T10 lesion with enhancement) that has failed to respond to high-dose IV methylprednisolone after 48 hours. Key discriminating findings: (1) steroid-refractory acute demyelinating attack, (2) severe neurologic deficit, (3) established MS diagnosis with CSF confirmation. The keyed answer (A, plasma exchange) is the standard second-line therapy for acute MS relapses unresponsive to corticosteroids, supported by AAN guidelines and clinical trials showing benefit in severe attacks. Option B (rituximab) and E (natalizumab) are disease-modifying therapies for long-term relapse prevention, not acute management. Option C (fingolimod) requires stable disease and has immunosuppressive effects that could worsen active inflammation. Option D (repeat LP) adds no diagnostic value when MS is already confirmed with typical CSF findings. The item is logically valid with a single defensible best answer matching the key. Medical accuracy is excellent, reflecting current standard of care for steroid-refractory MS relapses. No fix needed; this is a well-constructed board-style question testing appropriate escalation in acute demyelinating disease.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a severe acute MS relapse (transverse myelitis pattern with bilateral leg weakness, urinary retention, T10 lesion with enhancement) that has failed to respond to high-dose IV methylprednisolone after 48 hours. Key discriminating findings: (1) steroid-refractory acute demyelinating attack, (2) severe neurologic deficit, (3) established MS diagnosis with CSF confirmation. The keyed answer (A, plasma exchange) is the standard second-line therapy for acute MS relapses unresponsive to corticosteroids, supported by AAN guidelines and clinical trials showing benefit in severe attacks. Option B (rituximab) and E (natalizumab) are disease-modifying therapies for long-term relapse prevention, not acute management. Option C (fingolimod) requires stable disease and has immunosuppressive effects that could worsen active inflammation. Option D (repeat LP) adds no diagnostic value when MS is already confirmed with typical CSF findings. The item is logically valid with a single defensible best answer matching the key. Medical accuracy is excellent, reflecting current standard of care for steroid-refractory MS relapses. No fix needed; this is a well-constructed board-style question testing appropriate escalation in acute demyelinating disease.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-002", "question": "A 62-year-old woman with incomplete tetraplegia from a C5 spinal cord injury undergoes inpatient rehabilitation. She develops orthostatic hypotension during tilt table training, with blood pressure dropping from 120/80 mmHg supine to 85/50 mmHg at 60 degrees. Heart rate increases minimally. Autonomic testing shows absent sympathetic skin response below the lesion. What is the most effective pharmacologic intervention to facilitate upright tolerance?", "options": ["Midodrine", "Fludrocortisone", "Propranolol", "Clonidine", "Ephedrine"], "answer": "A", "answer_index": 0, "explanation": "Midodrine, an alpha-1 agonist, is the most effective for neurogenic orthostatic hypotension in spinal cord injury by promoting vasoconstriction without significant supine hypertension risk. Fludrocortisone causes fluid retention but risks edema; propranolol and clonidine may worsen hypotension, while ephedrine is less selective and has more side effects.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 62-year-old woman with C5 tetraplegia developing neurogenic orthostatic hypotension (OH) during tilt table training, evidenced by significant BP drop (120/80→85/50 mmHg) with minimal heart rate compensation and absent sympathetic skin response below the lesion. Key discriminating findings: high cervical SCI, autonomic dysfunction, symptomatic OH during rehabilitation. The question asks for the most effective pharmacologic intervention. Midodrine (A), an alpha-1 selective agonist, is first-line for neurogenic OH per consensus guidelines, providing direct vasoconstriction with rapid onset and minimal supine hypertension risk. Fludrocortisone (B) is second-line, slower-acting, and carries edema/fluid retention risks. Propranolol (C) and clonidine (D) would worsen hypotension by reducing sympathetic tone. Ephedrine (E) is less selective with more cardiac side effects and tachyphylaxis. The keyed answer aligns with standard SCI rehabilitation protocols and autonomic dysfunction management. No logical flaws exist; the stem provides sufficient detail to identify a unique best answer. Medical accuracy is excellent, reflecting current evidence-based practice. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 62-year-old woman with C5 tetraplegia developing neurogenic orthostatic hypotension (OH) during tilt table training, evidenced by significant BP drop (120/80→85/50 mmHg) with minimal heart rate compensation and absent sympathetic skin response below the lesion. Key discriminating findings: high cervical SCI, autonomic dysfunction, symptomatic OH during rehabilitation. The question asks for the most effective pharmacologic intervention. Midodrine (A), an alpha-1 selective agonist, is first-line for neurogenic OH per consensus guidelines, providing direct vasoconstriction with rapid onset and minimal supine hypertension risk. Fludrocortisone (B) is second-line, slower-acting, and carries edema/fluid retention risks. Propranolol (C) and clonidine (D) would worsen hypotension by reducing sympathetic tone. Ephedrine (E) is less selective with more cardiac side effects and tachyphylaxis. The keyed answer aligns with standard SCI rehabilitation protocols and autonomic dysfunction management. No logical flaws exist; the stem provides sufficient detail to identify a unique best answer. Medical accuracy is excellent, reflecting current evidence-based practice. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-003", "question": "A 28-year-old woman presents with recurrent episodes of vertigo, tinnitus, and fluctuating hearing loss, now with superimposed gait instability. MRI reveals bilateral vestibular schwannomas and a spinal ependymoma. Genetic testing confirms NF2 mutation. She develops progressive bilateral facial weakness. What is the most appropriate targeted therapy to consider for tumor stabilization?", "options": ["Bevacizumab", "Everolimus", "Crizotinib", "Trametinib", "Sorafenib"], "answer": "A", "answer_index": 0, "explanation": "Bevacizumab, a VEGF inhibitor, is the most appropriate for NF2-associated schwannomas by reducing tumor vascularity and stabilizing growth, with evidence from clinical trials showing hearing preservation. Everolimus targets mTOR but lacks specificity for NF2; crizotinib, trametinib, and sorafenib are not indicated for this condition and target unrelated pathways.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes classic NF2 (bilateral vestibular schwannomas, spinal ependymoma, confirmed NF2 mutation) with progressive symptoms requiring targeted therapy. Key discriminating findings: bilateral vestibular schwannomas in young patient, confirmed NF2 mutation, progressive symptoms including bilateral facial weakness indicating tumor growth. Bevacizumab (anti-VEGF) is the only FDA-approved targeted therapy for NF2-associated vestibular schwannomas, supported by clinical trials (e.g., Plotkin 2009, 2012) demonstrating tumor volume reduction and hearing improvement/stabilization. The keyed answer A is medically accurate and uniquely defensible. Alternative assessment: Everolimus (B) targets mTOR and has been studied in NF2 but lacks the evidence base of bevacizumab and is not standard of care. Crizotinib (C), trametinib (D), and sorafenib (E) target ALK/ROS1, MEK, and multi-kinase pathways respectively—none have established roles in NF2 management. No logical flaws exist; the stem provides sufficient detail to identify NF2 requiring targeted therapy, and only bevacizumab has evidence-based support for this indication. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes classic NF2 (bilateral vestibular schwannomas, spinal ependymoma, confirmed NF2 mutation) with progressive symptoms requiring targeted therapy. Key discriminating findings: bilateral vestibular schwannomas in young patient, confirmed NF2 mutation, progressive symptoms including bilateral facial weakness indicating tumor growth. Bevacizumab (anti-VEGF) is the only FDA-approved targeted therapy for NF2-associated vestibular schwannomas, supported by clinical trials (e.g., Plotkin 2009, 2012) demonstrating tumor volume reduction and hearing improvement/stabilization. The keyed answer A is medically accurate and uniquely defensible. Alternative assessment: Everolimus (B) targets mTOR and has been studied in NF2 but lacks the evidence base of bevacizumab and is not standard of care. Crizotinib (C), trametinib (D), and sorafenib (E) target ALK/ROS1, MEK, and multi-kinase pathways respectively—none have established roles in NF2 management. No logical flaws exist; the stem provides sufficient detail to identify NF2 requiring targeted therapy, and only bevacizumab has evidence-based support for this indication. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-004", "question": "A 55-year-old man with diabetic amyotrophy presents for outpatient rehabilitation with severe proximal leg weakness and pain. Electromyography shows denervation in the L2-L4 myotomes. Despite optimized glycemic control, he has persistent muscle atrophy. What is the most evidence-based adjunctive therapy to enhance functional recovery beyond standard physical therapy?", "options": ["Intravenous immunoglobulin", "Pyridostigmine", "Gabapentin", "Corticosteroids", "Plasmapheresis"], "answer": "A", "answer_index": 0, "explanation": "Intravenous immunoglobulin has shown benefit in diabetic amyotrophy by modulating autoimmune-mediated nerve damage, leading to improved strength and pain control in refractory cases. Corticosteroids risk worsening diabetes; pyridostigmine is for myasthenia, gabapentin addresses pain but not weakness, and plasmapheresis lacks supporting evidence.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The stem describes diabetic amyotrophy (diabetic lumbosacral radiculoplexus neuropathy) with proximal leg weakness, pain, and denervation in L2-L4 myotomes despite optimized glycemic control. The question asks for the most evidence-based adjunctive therapy beyond physical therapy. Key issue: The evidence base for immunomodulatory treatments in diabetic amyotrophy is limited and controversial. While small case series and retrospective studies suggest potential benefit from IVIG (option A) and corticosteroids (option D), neither has robust randomized controlled trial evidence establishing superiority. The stem does not provide sufficient clinical context (disease severity, duration, prior treatment failures) to distinguish between these immunomodulatory approaches. Both IVIG and corticosteroids have been reported in the literature with similar levels of evidence quality. The rationale's dismissal of corticosteroids due to diabetes worsening risk is a clinical consideration but does not eliminate it as a defensible option when disease severity warrants immunomodulation. The item requires an unstated assumption about which limited-evidence therapy is \\\"most evidence-based.\\\" Medical accuracy: The teaching point oversimplifies a nuanced area where evidence is weak for all immunomodulatory options. Minimal fix: Specify \\\"in a patient with contraindications to corticosteroids\\\" or provide stronger clinical context favoring IVIG specifically.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The stem describes diabetic amyotrophy (diabetic lumbosacral radiculoplexus neuropathy) with proximal leg weakness, pain, and denervation in L2-L4 myotomes despite optimized glycemic control. The question asks for the most evidence-based adjunctive therapy beyond physical therapy. Key issue: The evidence base for immunomodulatory treatments in diabetic amyotrophy is limited and controversial. While small case series and retrospective studies suggest potential benefit from IVIG (option A) and corticosteroids (option D), neither has robust randomized controlled trial evidence establishing superiority. The stem does not provide sufficient clinical context (disease severity, duration, prior treatment failures) to distinguish between these immunomodulatory approaches. Both IVIG and corticosteroids have been reported in the literature with similar levels of evidence quality. The rationale's dismissal of corticosteroids due to diabetes worsening risk is a clinical consideration but does not eliminate it as a defensible option when disease severity warrants immunomodulation. The item requires an unstated assumption about which limited-evidence therapy is \"most evidence-based.\" Medical accuracy: The teaching point oversimplifies a nuanced area where evidence is weak for all immunomodulatory options. Minimal fix: Specify \"in a patient with contraindications to corticosteroids\" or provide stronger clinical context favoring IVIG specifically.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}]